The Latest ALS News: Expanded access program for ALS drug MN-166 at 50% enrollment. ALSNewsToday.com

ALS Access Update: https://bit.ly/3MtWLSG

An expanded access program for the experimental therapy MN 166 has reached fifty percent enrollment.

#ALS #ALSNewsToday #Bionews #ALSResearch #ExpandedAccess #ClinicalTrials #ALSTreatment #RareDiseaseNews

The Latest CF News: CF treatment Trikafta boosts lung function for patients over 40, a study found. Cystic Fibrosis - News Today.

See what this study found: https://bit.ly/45xNKOU

New research suggests Trikafta improved lung function and reduced flare ups in people with cystic fibrosis who started treatment after age 40.

#CysticFibrosis #CysticFibrosisNewsToday #Bionews #CFResearch #CFCommunity #RareDiseaseNews #CFTreatment

The Latest ALS News highlights Radicava and Radicava ORS management transfer to a U.S. organization, ensuring patient access.

Understand what this means: https://bit.ly/4jG1I7c

Radicava and Radicava ORS are entering a new phase of management, with plans focused on keeping access stable for people living with ALS.

#ALS #AmyotrophicLateralSclerosis #ALSTreatment #RareDisease #RareDiseaseNews #ALSNewsToday #Bionews

"The Latest ALS News: APRTX-003 is an experimental RNA therapy for ALS, targeting MMP 9 enzyme to reduce nerve cell damage. Preclinical trials ongoing."

New ALS research: https://bit.ly/4qg1JkM

APRTX-003 is an experimental RNA based therapy designed to reduce MMP 9, an enzyme associated with nerve cell damage.

#ALSNewsToday #ALSResearch #ALSScience #NeurodegenerativeDisease #RareDiseaseNews #Bionews

Year in review: https://bit.ly/3YbmstE

From major treatment approvals to research that pushed understanding of MG forward, these were the most read Myasthenia Gravis News stories of 2025.

#MyastheniaGravis #MyastheniaGravisNews #MGResearch #ClinicalTrials #MGCommunity #RareDiseaseNews #Bionews